---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-043290"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T11:41:52.818926+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# ImmuCell Q1 product sales up 11% to $8.1M, net income $1.4M ($0.16 EPS) vs loss year ago

## Summary
- Q1 product sales $8.1M (record high), up 11% YoY; 6-month sales $15.8M (+28%).
- Net income $1.4M ($0.16 diluted EPS) vs net loss of $438K ($0.06 loss) in Q1 2024.
- Gross margin improved to 42% from 32% YoY; adjusted EBITDA $2.3M for Q1.
- Cash $4.6M, no draw on $1M line; working capital $12.1M, equity $29M.
- Contract manufacturer issues delay Re-Tain; company exploring strategic options for the technology.

## SEC filing metadata
- accession: 0001213900-25-043290
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390025043290/0001213900-25-043290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390025043290/ea0241943-8k_immucell.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-043290
- JSON: https://secwatch.observer/filing/0001213900-25-043290.json
- Plain text: https://secwatch.observer/filing/0001213900-25-043290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.